
Assembly Biosciences (ASMB) Stock Forecast & Price Target
Assembly Biosciences (ASMB) Analyst Ratings
Bulls say
Assembly Biosciences is a promising clinical-stage biotechnology company with a diverse pipeline of innovative therapies for viral infections, including recurrent genital herpes, hepatitis delta virus, and hepatitis B virus. The company's strong balance sheet and ongoing partnerships with industry leaders like Gilead offer significant potential for long-term success, while the recent opt-in decision from Gilead for the HSV program further validates the company's innovative approach. Additionally, the company's high-profile collaborations and diverse portfolio add significant optionality for future growth and positive returns for shareholders.
Bears say
Assembly Biosciences is still in the clinical stage and has yet to produce any products for commercialization, making it a risky investment. While the company's pipeline shows potential, competition already exists in the HSV market and their products may not be able to compete with established treatments. Additionally, without any approved products, it is difficult to accurately predict potential revenue and market share for Assembly Biosciences.
This aggregate rating is based on analysts' research of Assembly Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Assembly Biosciences (ASMB) Analyst Forecast & Price Prediction
Start investing in Assembly Biosciences (ASMB)
Order type
Buy in
Order amount
Est. shares
0 shares